Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C, Van Praagh I, Delva R, Leduc B, Fleury J, Gamelin E, Sillet-Bach I, Penault-Llorca F, Amat S, Chollet P. Abrial C, et al. Among authors: van praagh i. Oncologist. 2005 Apr;10(4):242-9. doi: 10.1634/theoncologist.10-4-242. Oncologist. 2005. PMID: 15821244 Free article. Clinical Trial.
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Wang-Lopez Q, Mouret-Reynier MA, Savoye AM, Abrial C, Kwiatkowski F, Garbar C, DuBray-Longeras P, Eymard JC, Lebouedec G, Vanpraagh I, Penault-Llorca F, Chollet P, Cure H. Wang-Lopez Q, et al. Oncologist. 2015 Mar;20(3):243-4. doi: 10.1634/theoncologist.2014-0400. Epub 2015 Jan 30. Oncologist. 2015. PMID: 25637380 Free PMC article. Clinical Trial.
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I. Fargeot P, et al. Among authors: van praagh i. J Clin Oncol. 2004 Dec 1;22(23):4622-30. doi: 10.1200/JCO.2004.02.145. Epub 2004 Oct 25. J Clin Oncol. 2004. PMID: 15505276 Clinical Trial.
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Bonneterre J, Roché H, Kerbrat P, Fumoleau P, Goudier MJ, Fargeot P, Montcuquet P, Clavère P, Barats JC, Monnier A, Veyret C, Datchary J, Van Praagh I, Chapelle-Marcillac I. Bonneterre J, et al. Among authors: van praagh i. J Clin Oncol. 2004 Aug 1;22(15):3070-9. doi: 10.1200/JCO.2004.03.098. J Clin Oncol. 2004. PMID: 15284257 Clinical Trial.
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Pouget M, Abrial C, Planchat E, Van Praagh I, Arbre M, Kwiatkowski F, Dubray-Longeras P, Devaud H, Dohou J, Herviou P, Mahammedi H, Durando X, Chollet P, Mouret-Reynier MA. Pouget M, et al. Among authors: van praagh i. Oncology. 2015;89(6):319-31. doi: 10.1159/000437230. Epub 2015 Oct 13. Oncology. 2015. PMID: 26457979
36 results